Levine E G, Arthur D C, Frizzera G, Peterson B A, Hurd D D, Bloomfield C D
Department of Medicine, University of Minnesota Health Sciences Center, Minneapolis.
Ann Intern Med. 1988 Jan;108(1):14-20. doi: 10.7326/0003-4819-108-1-14.
Tumor cytogenetic analysis was done for 68 patients with newly diagnosed non-Hodgkin lymphoma, and recurring cytogenetic abnormalities were correlated with achievement of complete remission, duration of complete remission, and survival. Among all patients, the presence of normal metaphases in tumor material was associated with a higher complete remission rate and longer survival. However, the duration of complete remission did not correlate with the presence or absence of chromosomal changes. Among patients with follicular lymphomas, the presence of normal metaphases in the tumor material was again associated with a higher rate of complete remission and with longer survival. Patients with structural abnormalities of chromosome 17 had a shorter survival than patients without these abnormalities. Among the patients with diffuse large-cell and immunoblastic lymphomas, those with breaks in the short arm of chromosome 2 had a longer survival than those without these breaks. We conclude that chromosomal abnormalities are predictive of clinical outcome in malignant lymphoma.
对68例新诊断的非霍奇金淋巴瘤患者进行了肿瘤细胞遗传学分析，并将复发性细胞遗传学异常与完全缓解的达成、完全缓解的持续时间及生存率相关联。在所有患者中，肿瘤组织中正常中期相的存在与较高的完全缓解率及较长的生存期相关。然而，完全缓解的持续时间与染色体改变的有无并无关联。在滤泡性淋巴瘤患者中，肿瘤组织中正常中期相的存在再次与较高的完全缓解率及较长的生存期相关。有17号染色体结构异常的患者比无这些异常的患者生存期短。在弥漫性大细胞和免疫母细胞淋巴瘤患者中，有2号染色体短臂断裂的患者比无这些断裂的患者生存期长。我们得出结论，染色体异常可预测恶性淋巴瘤的临床结局。
